The inhibition of the activation of several glucose metabolic gene promoters by an RORγ-selective antagonist, thereby mimicking the effects in RORγ−/− liver, suggests that such antagonists might provide a novel therapeutic strategy in the management of insulin resistance and type 2 diabetes. This evidence concerns the gene RORC and Insulin resistance.